Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Curis, Inc. CRIS

Healthcare  —  Biotechnology
0.83 (0.05) (5.68%) as of 25 Sep
Market cap
$1.8M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Curis, Inc. (CRIS) Business Profile

Updated before January 2025

Company Overview

Curis, Inc. (NASDAQ: CRIS) is a biotechnology company dedicated to the development and commercialization of innovative therapeutics for the treatment of cancer. Founded in 2000 and headquartered in Lexington, Massachusetts, Curis has been at the forefront of advancing targeted cancer therapies. The company’s mission is to improve the lives of patients by developing cutting-edge treatments that address unmet medical needs in oncology.

Curis is led by a team of experienced professionals in the biotechnology and pharmaceutical industries. The company’s leadership includes James E. Dentzer, who serves as the President and Chief Executive Officer. Under his guidance, Curis has focused on leveraging its expertise in signaling pathway modulation to develop novel therapies. The company’s scientific advisory board comprises leading experts in oncology and drug development, further strengthening its research and development capabilities.

Core Business Segments

Curis operates primarily in the field of oncology, with a focus on targeted therapies. The company’s core business segments include the following:

1. Small Molecule Inhibitors

Curis develops small molecule inhibitors that target specific signaling pathways involved in cancer progression. Key products in this category include:

  • Fimepinostat (CUDC-907): A dual inhibitor of HDAC and PI3K enzymes, designed to treat hematologic malignancies and solid tumors.
  • CA-4948: A first-in-class IRAK4 kinase inhibitor, currently being evaluated for the treatment of hematologic cancers such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

2. Immuno-Oncology

Curis is also exploring the potential of immuno-oncology therapies to harness the body’s immune system to fight cancer. The company’s pipeline includes:

  • CI-8993: A monoclonal antibody targeting VISTA (V-domain Ig suppressor of T cell activation), aimed at enhancing immune response against tumors.

3. Collaborative Programs

Curis collaborates with other biotechnology and pharmaceutical companies to advance its research and development efforts. Notable partnerships include collaborations with Aurigene Discovery Technologies for the development of small molecule inhibitors and with Genentech for the commercialization of Erivedge® (vismodegib), a hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma.

Business Model

Curis’s business model is centered on innovation, collaboration, and commercialization. The company generates revenue through a combination of product sales, licensing agreements, and milestone payments from its collaborative programs. Key aspects of its business model include:

  • Research and Development (R&D): Curis invests heavily in R&D to discover and develop novel therapies. The company’s focus on targeted therapies and immuno-oncology positions it as a leader in the oncology space.
  • Partnerships: Strategic collaborations with industry leaders enable Curis to leverage external expertise and resources, accelerating the development and commercialization of its products.
  • Revenue Streams: Curis earns revenue from product sales, royalties, and milestone payments. For example, the company receives royalties from Genentech for sales of Erivedge®.

Strategic Direction

Curis is committed to advancing its pipeline of innovative cancer therapies and expanding its presence in the oncology market. Key strategic priorities include:

  • Pipeline Expansion: Curis aims to advance its existing pipeline candidates, such as CA-4948 and CI-8993, through clinical trials and regulatory approval processes.
  • New Indications: The company is exploring additional indications for its therapies to maximize their therapeutic potential.
  • Sustainability Goals: Curis is dedicated to conducting its operations in an environmentally and socially responsible manner, aligning with broader sustainability objectives.
  • Global Reach: Curis seeks to expand its global footprint by entering new markets and forming strategic alliances with international partners.

Competitive Landscape

Curis operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Bristol-Myers Squibb: A leader in immuno-oncology with a robust portfolio of cancer therapies.
  • Novartis: Known for its innovative targeted therapies and strong presence in oncology.
  • Blueprint Medicines: A biotechnology company specializing in precision therapies for cancer.
  • Incyte Corporation: Focused on developing targeted therapies and immuno-oncology treatments.

Despite the competitive landscape, Curis differentiates itself through its focus on novel signaling pathways and its collaborative approach to drug development.

Risk Factors

Like any biotechnology company, Curis faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Regulatory Challenges: The development and approval of new therapies are subject to stringent regulatory requirements, which can be time-consuming and costly.
  • Market Dependence: Curis relies heavily on the success of its pipeline candidates and collaborative programs for revenue generation.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply chain for raw materials and manufacturing processes.
  • Competition: Intense competition in the oncology market could limit Curis’s market share and profitability.
  • Financial Risks: As a clinical-stage company, Curis may face challenges in securing adequate funding to support its R&D activities and operational expenses.

Recent Developments

Curis has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trials: The company has initiated and advanced multiple clinical trials for its pipeline candidates, including CA-4948 and CI-8993.
  • Partnerships: Curis has strengthened its collaboration with Aurigene Discovery Technologies to accelerate the development of small molecule inhibitors.
  • COVID-19 Impact: The global pandemic has posed challenges to clinical trial timelines and supply chain operations, but Curis has implemented measures to mitigate these impacts.

Investment Considerations

Investors considering Curis as a potential investment should weigh the following factors:

Strengths:

  • Strong focus on innovative cancer therapies with significant market potential.
  • Robust pipeline of targeted therapies and immuno-oncology candidates.
  • Strategic partnerships with industry leaders, providing additional resources and expertise.

Risks:

  • Dependence on the success of pipeline candidates for future revenue growth.
  • High R&D expenses and potential delays in clinical trials.
  • Competitive pressures in the oncology market.

Conclusion

Curis, Inc. is a pioneering biotechnology company with a strong focus on developing targeted cancer therapies. With a robust pipeline, strategic partnerships, and a commitment to innovation, Curis is well-positioned to address unmet medical needs in oncology. While the company faces challenges such as regulatory hurdles and market competition, its strategic direction and recent developments underscore its potential for long-term growth. As Curis continues to advance its pipeline and expand its global presence, it remains a compelling player in the biotechnology sector.